← Back to Search

Procedure

TOETVA for Thyroid Disease

Phase 1
Waitlist Available
Led By Jesse D Pasternak, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This study is evaluating whether a minimally invasive procedure is safe and feasible for treating trigeminal neuralgia.

Eligible Conditions
  • Thyroid Disease
  • Surgery

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Length of stay
Neck incision
Post-operative recurrent laryngeal nerve palsy
+8 more
Secondary outcome measures
Quality of Life Score

Trial Design

1Treatment groups
Experimental Treatment
Group I: TOETVAExperimental Treatment1 Intervention
Transoral Endoscopic Thyroidectomy Vestibular Approach
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TOETVA
2019
N/A
~20

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,468 Previous Clinical Trials
484,475 Total Patients Enrolled
Jesse D Pasternak, MDPrincipal InvestigatorUniversity Health Network, Toronto

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025